$BBIO · BridgeBio Pharma, Inc.
BridgeBio Pharma filed its Q3 2026 10-Q, reporting total revenues of $353.2M (+192.6% YoY), driven primarily by Attruby (acoramidis) net product revenue of $253.3M. Loss from operations narrowed dramatically to $(11.6M) from $(145.2M) a year ago. Net loss attributable to BridgeBio was $(56.7M), or $(0.42) per share. The company held $1.22B in cash, cash equivalents, and marketable securities as of September 30, 2026.
- Q3 2026 total revenue of $353.2M, up 192.6% YoY from $120.7M, driven by Attruby net product revenue of $253.3M.
- Loss from operations narrowed to $(11.6M) from $(145.2M) in Q3 2025 — a 92% improvement.
- Nine-month revenue reached $791.4M vs $347.9M in the prior-year period, with net product revenue at $656.4M.
- Cash, cash equivalents, and marketable securities totaled $1.22B as of September 30, 2026, up from $187.9M at year-end 2025.
- Preferred stock dividends and accretion of $26.3M widened the gap between net loss attributable to BridgeBio ($56.7M) and net loss attributable to common stockholders ($83.0M).
Extended-hours trading shows minimal movement at $70.72 (-0.01% vs regular close), suggesting the strong revenue ramp and narrowing losses were largely priced in. The $13.83B market cap reflects high expectations already embedded for the Attruby launch trajectory.
BridgeBio's near-breakeven quarter validates the Attruby commercial thesis and signals the rare-disease platform may self-fund its pipeline without additional dilutive financing.
BridgeBio's 193% revenue growth and near-breakeven operating performance place it among the more successful rare-disease commercial launches, contrasting with peers still burning cash pre-revenue. The $1.22B cash position provides runway to fund the pipeline (low-dose infigratinib, encaleret, BBP-418) without imminent dilution risk.
Heavy reliance on Attruby and Beyonttra commercial success; any setback in market acceptance, pricing, or reimbursement would disproportionately impact results. The $533.6M fair value of the Funding Agreement and $338.8M deferred royalty obligation represent significant non-operating liabilities.